Evidence map›Paper›PMID 40911342›Full record

ReviewEuropean journal of immunology2025

Beyond Negative Regulation: IL-1R8 and IL-1R2 as Novel Immune Checkpoints.

Domenico Supino, Roberto Garuti, Cecilia Garlanda

Abstract readReview
In one paragraph

Review in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Domenico SupinoIRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0001-9690-1791
Roberto GarutiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.ORCID 0009-0008-8551-8832
Cecilia GarlandaIRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-1510-7703

Funding

European Union-Next Generation EU-PNRR-MAD-2022-12375947European Union-Next Generation PNC-E3-2022-23683266Ministry of University and Research 2022NKEXATMinistry of University and Research PRIN-20174T7NXL
6 · The paper itself

Abstract

IL-1 family members and their signaling receptors are key drivers of inflammation in sterile or infectious conditions, as well as polarization of the innate and adaptive immunity. Deregulated or excessive activation of the IL-1 system is associated with detrimental inflammatory reactions. Beside signaling receptors, IL-1-family receptors comprise decoy or negative regulatory receptors, which regulate cell activation mediated by IL-1 family ligands. IL-1-family negative regulatory receptors, which include IL-1R8 and IL-1R2, have peculiar structural features and functions essential to the self-regulation of the IL-1 system. IL-1R8 and IL-1R2 emerge as regulatory molecules whose function is context-dependent, spanning from negative regulation of inflammation in infections or conditions of sterile inflammation and cell damage, including cancer-related inflammation, to skewing of myeloid and lymphoid cells, modulation of anti-tumor immunity, and immune checkpoint activity. This review reports new insights into the physio-pathological roles of these two negative regulatory IL-1 family members, emphasizing their mechanisms of action and potential for innovative therapeutic interventions.

Indexed as

Receptors, Interleukin-1 Type IIAnimalsHumansInflammationNeoplasmsSignal TransductionReceptors, Interleukin-1 Type IIcytokinesinflammationinhibitory receptorsinnate immunity

Identifiers

PMID40911342
PMCPMC12412433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.